Merck, Inc.
🇺🇸United States
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)
Phase 3
Completed
- Conditions
- Postoperative Pain
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2015-08-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 450
- Registration Number
- NCT00092300
A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT00092846
Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED)
Phase 3
Completed
- Conditions
- Cervical CancerGenital Warts
- Interventions
- Biological: Human Papillomavirus (HPV) 16 MonovalentBiological: V501
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2015-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5759
- Registration Number
- NCT00092521
A 2-Year Study of an Investigational Drug in Obese Patients (0557-011)
Phase 3
Completed
- Conditions
- Obesity
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT00092859
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015)
Phase 3
Active, not recruiting
- Conditions
- Cervical CancerGenital Warts
- Interventions
- Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccineBiological: Matching Placebo
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12167
- Registration Number
- NCT00092534
A Study of Gardasil (V501) in Preadolescents and Adolescents (V501-018)
Phase 3
Completed
- Conditions
- Papillomavirus InfectionsHuman
- Interventions
- Biological: V501
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2018-02-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1781
- Registration Number
- NCT00092547
A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)
Phase 3
Completed
- Conditions
- Obesity
- First Posted Date
- 2004-09-28
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 359
- Registration Number
- NCT00092872
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182)
Phase 3
Completed
- Conditions
- Postoperative Pain
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 271
- Registration Number
- NCT00092313
Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)
Phase 2
Completed
- Conditions
- RubellaMeaslesVaricellaMumps
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1210
- Registration Number
- NCT00092404
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)
Phase 3
Completed
- Conditions
- Postoperative Pain
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2016-02-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 269
- Registration Number
- NCT00092326
© Copyright 2025. All Rights Reserved by MedPath